Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemoglobinuria, Paroxysmal | 5 | 2020 | 7 | 2.970 |
Why?
|
| Myelodysplastic Syndromes | 8 | 2020 | 41 | 2.190 |
Why?
|
| Primary Myelofibrosis | 4 | 2020 | 8 | 1.150 |
Why?
|
| Blood Transfusion | 3 | 2020 | 65 | 0.810 |
Why?
|
| Thrombocythemia, Essential | 2 | 2022 | 3 | 0.770 |
Why?
|
| Complement System Proteins | 1 | 2020 | 15 | 0.740 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 115 | 0.730 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 260 | 0.690 |
Why?
|
| Polycythemia Vera | 4 | 2022 | 6 | 0.690 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 6 | 0.670 |
Why?
|
| Phthalazines | 1 | 2019 | 8 | 0.670 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2016 | 4 | 0.660 |
Why?
|
| Iron Chelating Agents | 1 | 2018 | 1 | 0.630 |
Why?
|
| Iron Overload | 1 | 2018 | 3 | 0.630 |
Why?
|
| Transfusion Reaction | 1 | 2018 | 9 | 0.620 |
Why?
|
| Piperazines | 1 | 2019 | 91 | 0.620 |
Why?
|
| Hemochromatosis | 1 | 2017 | 3 | 0.600 |
Why?
|
| Pyrazoles | 3 | 2022 | 54 | 0.570 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 2 | 0.560 |
Why?
|
| Mutation, Missense | 1 | 2016 | 23 | 0.560 |
Why?
|
| Humans | 30 | 2022 | 30997 | 0.480 |
Why?
|
| Prognosis | 10 | 2021 | 919 | 0.440 |
Why?
|
| Hemolysis | 2 | 2020 | 8 | 0.370 |
Why?
|
| Hydrazines | 1 | 2010 | 8 | 0.370 |
Why?
|
| Benzoates | 1 | 2010 | 7 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2017 | 337 | 0.360 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 44 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2020 | 54 | 0.330 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 221 | 0.290 |
Why?
|
| Quality of Life | 3 | 2020 | 696 | 0.290 |
Why?
|
| Middle Aged | 15 | 2021 | 10195 | 0.270 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 31 | 0.270 |
Why?
|
| Survival Rate | 4 | 2021 | 404 | 0.250 |
Why?
|
| Female | 16 | 2021 | 16983 | 0.240 |
Why?
|
| Thrombosis | 2 | 2022 | 63 | 0.230 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 115 | 0.230 |
Why?
|
| Cost of Illness | 2 | 2020 | 56 | 0.220 |
Why?
|
| Thalidomide | 2 | 2017 | 7 | 0.220 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 8 | 0.210 |
Why?
|
| Thrombocytosis | 1 | 2022 | 3 | 0.210 |
Why?
|
| Aged | 12 | 2021 | 10048 | 0.200 |
Why?
|
| Disease Progression | 3 | 2020 | 830 | 0.200 |
Why?
|
| Nitriles | 1 | 2021 | 15 | 0.190 |
Why?
|
| Withholding Treatment | 1 | 2021 | 10 | 0.190 |
Why?
|
| Pyrimidines | 1 | 2021 | 28 | 0.190 |
Why?
|
| Salvage Therapy | 1 | 2021 | 40 | 0.190 |
Why?
|
| Complement C5 | 1 | 2020 | 2 | 0.190 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 16 | 0.190 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 13 | 0.190 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 52 | 0.180 |
Why?
|
| Leukocytosis | 1 | 2020 | 9 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2020 | 97 | 0.170 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 208 | 0.170 |
Why?
|
| Anemia | 1 | 2020 | 100 | 0.170 |
Why?
|
| Folic Acid | 1 | 2019 | 16 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 59 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 271 | 0.170 |
Why?
|
| Erythrocyte Transfusion | 3 | 2020 | 20 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 61 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2017 | 3806 | 0.150 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2017 | 1 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2017 | 42 | 0.140 |
Why?
|
| Blood Platelets | 2 | 2021 | 51 | 0.140 |
Why?
|
| Adult | 12 | 2020 | 8931 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2017 | 320 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 360 | 0.140 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2015 | 14 | 0.130 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 5189 | 0.120 |
Why?
|
| Male | 13 | 2021 | 16445 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 69 | 0.120 |
Why?
|
| Bone Marrow Examination | 1 | 2012 | 1 | 0.100 |
Why?
|
| Animals | 1 | 2020 | 4723 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2012 | 91 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2011 | 4 | 0.100 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 6 | 0.100 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 7 | 0.100 |
Why?
|
| Yttrium Radioisotopes | 1 | 2011 | 11 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 33 | 0.090 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2010 | 3 | 0.090 |
Why?
|
| Molecular Mimicry | 1 | 2010 | 5 | 0.090 |
Why?
|
| Bone Marrow Diseases | 1 | 2010 | 9 | 0.090 |
Why?
|
| Megakaryocytes | 1 | 2010 | 27 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2021 | 3658 | 0.090 |
Why?
|
| Remission Induction | 1 | 2010 | 105 | 0.090 |
Why?
|
| Data Collection | 1 | 2011 | 109 | 0.090 |
Why?
|
| Hematologic Agents | 1 | 2009 | 3 | 0.090 |
Why?
|
| Thrombopoietin | 1 | 2009 | 4 | 0.090 |
Why?
|
| Receptors, Fc | 1 | 2009 | 11 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2010 | 19 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 31 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2010 | 39 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 1922 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 191 | 0.080 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 10 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2011 | 39 | 0.070 |
Why?
|
| Rituximab | 3 | 2011 | 55 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2009 | 718 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2005 | 18 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 45 | 0.060 |
Why?
|
| Young Adult | 2 | 2020 | 2063 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2017 | 7 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2010 | 991 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 190 | 0.050 |
Why?
|
| Pyrroles | 1 | 2022 | 25 | 0.050 |
Why?
|
| Biomarkers | 2 | 2017 | 733 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 6 | 0.050 |
Why?
|
| Age Factors | 2 | 2017 | 873 | 0.050 |
Why?
|
| Quinazolines | 1 | 2022 | 27 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 64 | 0.050 |
Why?
|
| Platelet Count | 1 | 2021 | 22 | 0.050 |
Why?
|
| Granulocytes | 1 | 2020 | 23 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 25 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 409 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 203 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 295 | 0.040 |
Why?
|
| Vidarabine | 2 | 2011 | 12 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2011 | 22 | 0.040 |
Why?
|
| Neutropenia | 2 | 2011 | 23 | 0.040 |
Why?
|
| Cyclophosphamide | 2 | 2011 | 58 | 0.040 |
Why?
|
| Cytogenetics | 1 | 2017 | 3 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 6 | 0.040 |
Why?
|
| Azacitidine | 1 | 2017 | 12 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2017 | 81 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 404 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 2588 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 368 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1133 | 0.030 |
Why?
|
| Leukemia | 1 | 2013 | 10 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2013 | 52 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 44 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2011 | 5 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 2011 | 5 | 0.020 |
Why?
|
| Leukopenia | 1 | 2011 | 9 | 0.020 |
Why?
|
| Vincristine | 1 | 2011 | 27 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 500 | 0.020 |
Why?
|
| Prednisone | 1 | 2011 | 69 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2011 | 70 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 60 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 225 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 243 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 386 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 429 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 64 | 0.020 |
Why?
|
| Karyotyping | 1 | 2007 | 11 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 28 | 0.020 |
Why?
|
| Recurrence | 1 | 2005 | 370 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 2043 | 0.010 |
Why?
|
| Patient Selection | 1 | 2005 | 246 | 0.010 |
Why?
|